Novo Nordisk stock tumbles as Ozempic maker sets out 2030 goals

Novo Nordisk's stock took a dive on Monday as the company unveiled ambitious 2030 goals, but investors were left unconvinced about a near-term turnaround for the weight-loss drug maker. While the goals included expanding its drug portfolio and increasing market share, the lack of immediate specifics on how these targets will be achieved left many on the fence. This reaction underscores broader concerns about the company's ability to maintain its growth trajectory, especially given the competitive landscape in the pharmaceutical sector.